ITZ-1 is an orally active and selective extracellular signal-regulated kinase ( ERK )-mitogen-activated protein kinase ( MAPK ) pathway inhibitor with an IC 50 of 0.51 μM for inhibiting interleukin-1β (IL-1β)-induced matrix metalloproteinase-13 ( MMP-13 ) production. ITZ-1 reduces MMP-13 expression and suppresses nitric oxide (NO)-induced chondrocyte apoptosi. ITZ-1 is promising for research of osteoarticular diseases.
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > ERK | Products > Signaling Pathways > p38 MAPK
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.